Emily M. Leproust, an officer and director of Twist Bioscience Corp, filed a Form 144 notice on November 16, 2026, proposing the sale of 19,045 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ.
Key Highlights
- Proposed sale: 19,045 shares of Twist Bioscience Corp common stock with an aggregate market value of $1,974,745.58, according to the filing.
- Acquisition source: The shares were acquired on November 12, 2026, via restricted stock vesting from the issuer, with payment classified as compensation.
- Tax-related purpose noted: The filing states the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution."
- Shares outstanding: The filing lists 62,707,424 shares of common stock outstanding at the time of the notice.
- Prior three-month sales: Leproust reported ten separate sales of common stock between August 21, 2026, and November 3, 2026, totaling shares across those transactions.
- Largest prior transaction: A September 17, 2026, sale of 356,546 shares with gross proceeds of $56,330,878.38 was the largest individual transaction disclosed in the three-month history.
- Broker named: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is listed as the broker for the proposed sale.
Leproust's Form 144 Notice: Proposed Sale and Recent Transaction History at Twist Bioscience
According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission on November 16, 2026, Emily M. Leproust, identified as both an officer and director of Twist Bioscience Corp (NASDAQ:TWST), is proposing to sell 19,045 shares of the company's common stock. The filing lists an aggregate market value of $1,974,745.58 for the proposed shares. The notice designates Fidelity Brokerage Services LLC as the executing broker and lists the approximate date of sale as November 16, 2026.
The filing discloses that the 19,045 shares were acquired on November 12, 2026, through a restricted stock vesting transaction from the issuer, with the nature of payment listed as compensation. The filing includes a remark stating the sale "includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution." No other acquisition details or consideration beyond compensation are described for these shares.
As required by Rule 144, the filing also discloses Leproust's sales of Twist Bioscience common stock during the prior three months. Ten sales are listed, spanning August 21, 2026, through November 3, 2026. These transactions range from 655 shares sold on October 1, 2026, with gross proceeds of $131,000.00, to 356,546 shares sold on September 17, 2026, with gross proceeds of $56,330,878.38. The filing does not specify whether any of these prior sales were executed under a Rule 10b5-1 trading plan, though the signature block references the possibility of such a plan or trading instructions.
What Was Disclosed
Twist Bioscience Corp officer and director Emily M. Leproust filed a Form 144 notice proposing to sell 19,045 shares of common stock valued at $1,974,745.58, acquired November 12, 2026, via restricted stock vesting, with ten prior sales also disclosed for the preceding three months.





Please wait processing your request...